Corcept Disappoints With Depression Drug Data
Posted on: Monday, 2 October 2006, 12:01 CDT
Corcept Therapeutics has reported the failure of the second of its three phase III trials evaluating Corlux for treating psychotic major depression.
In August, Corcept said that the first of its trials for Corlux had failed. Corlux is Corcept's lead product in development.
The primary endpoint of the study was the proportion of patients with at least a 50% improvement in the Brief Psychiatric Rating Scale Positive Symptom Subscale. The study revealed no meaningful separation in response between patients receiving Corlux and patients receiving placebo. The two key secondary endpoints of the study were similarly negative.
"It is interesting to note that there was a statistically significant separation between the Corlux and placebo groups on an endpoint commonly used to measure the efficacy of antipsychotic and antidepressant medications, change from baseline to study end," said Joseph Belanoff, Corcept's CEO. "However, because of the already high degree of response in the placebo group, it is difficult to determine how much additional clinical utility is conferred by this finding."
Corcept will continue to enroll patients in another phase III study and has said it will announce the results of this trial early next year.
Source: Datamonitor
Related Articles
- Studies Show LAM Patients Participate in Clinical Trials to Help Others
- ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
- Regeneron's ARCALYST(R) (Rilonacept) Reduced Incidence of Gout Flares By 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-Lowering Therapy
- Glaucoma Surgery Studied in Medicare Patients
- Eculizumab is Well Tolerated and Demonstrates Significant Improvement During 52 Weeks of Treatment in Open-Label Phase III SHEPHERD Study in PNH Patients
- Effect of Three Months' Treatment With Irbesartan on Blood and Pulse Pressure of Hypertensive Type 2 Diabetic Patients: Open, Observational Study in 31793 Patients
- Clinical Study Demonstrates That CLEARANT PROCESS(R) Improves ACL Reconstructive Surgery Results; Study of 70 Patients Shows 0% Rate of Infection
- Studies Show Schizophrenia Patients Taking Atypicals Stayed on Treatment Longer Than Patients Taking Older, Typical Antipsychotics
- Economic Study in Surgical Patients of a New Model of Nutrition Therapy Integrating Hospital and Home Vs the Conventional Hospital Model
- The CARDS Investigators: Primary Prevention of Cardiovascular Disease With Atorvastatin in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre Randomised Placebo- Controlled Trial
 |
 |
User Comments (0)
RSS Feeds